专利检索 ap:("UNIVERSITY OF SASKATCHEWAN" OR "Bioniche Life Sciences Inc.") AND inv:"ROGAN, Dragan" 第 1 页

1.

发明公开
METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SHIGA TOXIN-PRODUCING ESCHERICHIA COLI INFECTION 有权
标题翻译：方法和组合物可用于治疗和预防滋贺县生产大肠杆菌感染

公开(公告)号：EP2417165A1

公开(公告)日：2012-02-15

申请号：EP10761153.5

申请日：2010-04-06

申请人： UNIVERSITY OF SASKATCHEWAN , Bioniche Life Sciences Inc.

发明人： POTTER, Andrew, A. , ASPER, David , ROGAN, Dragan

IPC分类号： C07K19/00 , A61K39/108 , A61K39/385 , A61P31/04 , A61P37/04 , C07K14/245

CPC分类号： A61K39/0258 , A61K2039/552 , A61K2039/55566 , A61K2039/6037 , C07K16/1232 , Y02A50/474

摘要： Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.

2.

发明授权
METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SHIGA TOXIN-PRODUCING ESCHERICHIA COLI INFECTION 有权
标题翻译：方法和组合物可用于治疗和预防滋贺县生产大肠杆菌感染

公开(公告)号：EP2417165B1

公开(公告)日：2016-05-25

申请号：EP10761153.5

申请日：2010-04-06

申请人： UNIVERSITY OF SASKATCHEWAN

发明人： POTTER, Andrew, A. , ASPER, David , ROGAN, Dragan

IPC分类号： C07K19/00 , A61K39/108 , A61K39/385 , A61P31/04 , A61P37/04 , C07K14/245

CPC分类号： A61K39/0258 , A61K2039/552 , A61K2039/55566 , A61K2039/6037 , C07K16/1232 , Y02A50/474

摘要： Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.